Inhibition of GLS also promotes the differentiation and effector functions of CD4+ Th1 and CD8+ CTL cells [108], while enhancing tumor sensitivity to radiotherapy [66], demonstrating that targeting GLS represents a potential strategy for ovarian cancer treatment. This evidence concerns the gene GLS and neoplasm.